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Abstract — Prostate cancer diagnosis is increasing, being the second most frequently cancer in men 
worldwide. The treatment of castrate-resistant prostate cancer is often unsuccessfully and new therapeutic 
interventions are searching for. Nucleic acid aptamers targeting eEF1A proteins are emerging molecular tools 
for the control of cancer growth. We found that an aptamer named GT75 was able to bind to eEF1A proteins 
of human prostate cancer cell lines and to significantly and specifically reduce their growth with respect to 
the control oligomer CT75. The highest anti-proliferation effect was found in the androgen-independent PC-3 
cells. Interestingly, GT75 was able to specifically inhibit the migration of PC-3 cells but not that of the non-
tumorigenic PZHPV-7 cells. The overall results suggest that the GT75 aptamer targeting eEF1A proteins is a 
promising molecular drug to develop for the control of the castrate-resistant prostate cancer.
Index Terms — Prostate cancer cell lines, castrate-resistant prostate cancer, aptamers, eEF1A, 
anti-proliferation effect
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1 BACKGROUND
Prostate cancer is a significant medical burden in men in the Western world being the second most 
frequently diagnosed cancer and the sixth leading cause of cancer death in males: 14% of the total new 
cancer cases and 6% of the total cancer deaths worldwide. It has been estimated that the year 2013 
witness 238,590 new prostate cancer cases and 29,720 prostate cancer deaths (1)  Although surgery, 
radiation, or both, can be curative for patients with localized disease, a significant proportion of these 
patients have recurrent disease which can lead to the development of metastases, especially in the high 
risk group – a transition to the lethal stage of the disease. Androgen depletion is the standard therapeutic 
treatment but after a period of stability, the tumor regrowth  as castration-resistant disease (15-20% of 
cases) (1). Castrate-resistant prostate cancer (CRPC) has limited therapeutic interventions and the survival 
is poor. The median survival of patients with metastatic CRPC is 12–16 months from the time of diagnosis 
to death (2). No curative treatments are available at this stage of the disease.
Aptamers  are nucleic acids selected to bind any molecules, protein included, in order to affect the 
biological activity of the cognate target that are raising as diagnostic and therapeutic tools (3). GT 
aptamers recognizing eukaryotic elongation factor 1A are single-stranded DNA strands discovered in 
2002 as anti-proliferative agents in hematopoietic human cancer cell lines, not affecting the growth of 
normal cells, that are able to increase the therapeutic index of conventional anti-cancer drugs too (4, 5). 
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2 APPROACH & METHODS
General approach
To  study the effect on cell growth/motility of a GT75 aptamer  in in vitro human prostate cancer 
model,  cell lines with different differentiation and androgen responsiveness  phenotypes 
(LNCaP, 22Rv1, PC-3) were used and compared with a non tumorigenic control cell line 
(PZHPV-7)
Methods
Immunofluorescence; Proliferation assay test (MTT);  Scratch test; Western-blotting, UV-
crosslinking assay; FACS
What new product or service might be realised thanks to your results?
New therapeutic intervention for the treatment of CRPC
Have you realised a prototype?  No
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Contacts/collaborations needed 
To do what:  cell biology and  molecular biology collaborations for  highlighting the basic mechanism 
of action of GT75 aptamer in prostate cell lines, especially regarding the interactions of GT75 with eEF1A 
isoforms and the modulation of genes and miRNA  expression by GT75 treatment. Collaborations on the 
in vivo effect of GT75 in CRPC animal models will be welcome.
Communication tools/strategy
Your 3 best scientific publications:
Scaggiante B, Dapas B, Farra R, Grassi M, Pozzato G, Giansante C, Fiotti N, Tamai E, Tonon F, Grassi G. 
Aptamers as targeting delivery devices or anti-cancer drugs for fighting tumors. Curr Drug Metab. 2013 
Jun;14(5):565-82.
Scaggiante B, Dapas B, Bonin S, Grassi M, Zennaro C, Farra R, Cristiano L, Siracusano S, Zanconati F, 
Giansante C, Grassi G. Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the 
potential of EEF1A2 as a hallmark for prostate transformation and progression. Br J Cancer. 2012 Jan 
3;106(1):166-73.
Scaggiante B, Bonin S, Cristiano L, Siracusano S, Stanta G, Dapas B, Giansante C, Fiotti N, Grassi G. Prostate-
tumor-inducing gene-1 analysis in human prostate cancer cells and tissue in relation to Mycoplasma 
infection. Cancer Invest. 2008 Oct;26(8):800-8. 
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Figure 1. Effects of the GT75 aptamer compared to the control oligomer CT75.  A) Binding of GT75 to eEF1A proteins 
that is marked by the presence of  the 50 kDa band (arrow) in cellular extracts of tumorigenic (LNCaP, 22RV1 and PC-
3) and non-tumorigenic (PZHPV-7) human prostate cell lines;  B) Effect of GT75 on the cellular growth of the human 
prostate cancer cell lines and of the non-tumorigenic cells (PZHPV-7); C) Effect of the GT75 on the migration of the 
PC-3 cells with respect to the non-tumorigenic PZHPV-7 cells.
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Your websites (Your project, Researchgate, LinkedIn, etc):Researchgate and LinkedIn
Your Facebook: Yes
4 OBJECTIVE(S)
• Highlighting the mechanism of action of GT75 in human prostate cancer cell lines; 
• Demonstrating the in vivo potential of GT75 in reducing tumor growth and in reversing drug-
resistance in CRPC animal models
• Developing  nucleic acid delivery methods based on polymeric and nano technologies for the in vivo 
release of GT75 for the in site treatment of  CRPC  
5 RESULTS
• By UV cross-linking competition assay we proved that a known eEF1A aptamer binder named GT27 
was  efficiently and specifically displaced  by GT75  using LNCaP, 22Rv1 and PC-3 extracts. This validated 
GT75 use as eEF1A aptamer in prostate cancer cells (fig.A)
• By MTT assay we observed that GT75 was able to significantly reduce the growth of cancer cells in a 
dose-dependent manner at nmolar doses with respect to a control sequence named CT75. The anti-
proliferative effect was minimal in androgen-dependent  LNCaP cell line and maximal in the androgen-
independent PC-3 cell line, resulting in: PC-3>22Rv1>LNCaP. Notably GT75 did not significantly affect 
the growth of the non-tumorigenic PZHPV-7 cells with respect to CT75 control (Fig.B)
• By stratch assay we demonstrated that GT75 efficiently reduced the PC-3 cell migration but not that 
of the non tumorigenic control PZHPV-7 (Fig. C)
• Finally, we observed that GT75 was able to specifically increase the effect of conventional drugs such 
as  bortezomib and idarubicin (not shown).
6 COLLABORATIONS
With other researchers (TRL0-4): Yes, those reported as co-authors
With SMEs (TRL5 -9)
With hospitals (TRL9): AOUTS- Cattinara-University of  Trieste
With associations (TRL9): LILT (Italian League against Cancer)
Funds needed (forecast)
For  basic research (investigation of biological mechanisms): € 20,000 consumables
For applied research (solutions for real-world problems): € 30,000 consumables + 30,000 (1 year fellowship)
For pilot & demonstrator activities (to develop a prototype) : € 20,000 consumables
